Navigation Links
BioMarin to Present at the Stifel Nicolaus Healthcare Conference
Date:9/9/2010

NOVATO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in Boston on Friday, September 17, 2010 at 9:10 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 ... investing £2.5 million to help it meet the ... goods, healthcare, pharmaceuticals and logistics. Albion joins Shackleton ... ) Over the past 18 months ... its platform, its management team and its operations. ...
(Date:7/25/2014)... July 25, 2014  Depomed, Inc. (NASDAQ: ... quarter fiscal year 2014 financial results after the market ... a conference call beginning at 4:30 pm EDT, 1:30 pm PDT ... the call by dialing 877-317-6789 ( United States ... also be available via a live webcast on the ...
(Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
Breaking Medicine Technology:OmPrompt Funded for Customer Automation Management Market Expansion 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... and LONDON, Nov. 20 Boston Scientific Corporation (NYSE: ... received 510(k) clearance from the U.S. Food and Drug ... WallFlex® Fully Covered Esophageal Stent for the treatment of ... with resectable or non-resectable esophageal cancer. , (Photo: ...
... , HOUSTON, Nov. 20 Cyberonics, Inc. (Nasdaq: CYBX ... and Greg Browne, Chief Financial Officer, will present at the 21st ... December 2, 2009 at 12:00 PM EST. The conference session ... be presented. Piper Jaffray will host a webcast of the ...
Cached Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2
(Date:7/28/2014)... a healthy lifestyle may help childhood cancer survivors reduce ... indicates. Researchers suggested that children with cancer and ... about how their diet and certain behaviors could ... are important because they indicate that adults who were ... influence their own health outcomes," said one of the ...
(Date:7/28/2014)... 28, 2014 Glidewell Laboratories announced today ... have successfully passed the five-year mark in clinical usage, ... million units prescribed by US dentists. , Even as ... with good results from respected clinical studies, many dentists ... perform over extended years of clinical service before they ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 This ... Global and Chinese Tadalafil industry. The report firstly ... classification, application and manufacturing technology. The report then ... listing their product specification, capacity, Production value, and ... quantitatively 2009-2014 global and China’s total market of ...
(Date:7/28/2014)... Raleigh, NC (PRWEB) July 28, 2014 ... they say is an improved blood test for the ... article on the new research. Click here to ... of Respiratory Medicine at Tokyo’s Juntendo University Graduate School ... biomarker called N-ER/mesothelin is a step above the old ...
(Date:7/28/2014)... July 28, 2014 Community Health Center ... medical, dental, and pharmacy services, has released an article ... chronic disease management . Founded in 1983, the health ... those of the county that face barriers to obtaining ... make an appointment at the CHC, click here: ...
Breaking Medicine News(10 mins):Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
... Youthful ... Appearance, BEVERLY HILLS, Calif., ... Hills, CA states,"Changing the size and shape of your teeth can significantly ... patients,say that a smile make-over is better than botox in restoring a ...
... Prime Therapeutics (Prime), a,thought leader in pharmacy ... joined the organization as Vice President of,Pharmacy Trade ... Relations, Wan will focus on,developing and maintaining relationships ... in the development of strategic pharmacy,contracts and the ...
... Corporation,(Nasdaq: DRAD ), a leading provider of ... hospitals and imaging centers, today,reported financial results for ... revenues were higher, compared to the same time ... imaging services revenues within Digirad,Imaging Solutions. The Company,s ...
... Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer ... announced that Phyhealth Plan Corporation, a wholly-owned subsidiary,of ... to provide,comprehensive vision services for its Pilot HMO ... 2008., Mr. Robert Trinka, chairman and chief ...
... C-Change champions the Cancer Patient Navigation Act on ... sets into motion,a world of confusion and questions ... navigation services brings the patient-focus,back to cancer care ... a,skilled navigator guide him or her thought the ...
... ST. LOUIS, April 23 Young Innovations, Inc.,(Nasdaq: YDNT ... Sales for the first quarter of 2008 were $24.4 ... million reported in the first quarter,of 2007. Income from operations ... from $4.7 million in the first quarter of 2007. Net ...
Cached Medicine News:Health News:'Size Does Matter ... and So Does Shape ... When It Comes to Teeth,' Says Cosmetic Dentist, Dr. Denise Fundora 2Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 2Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 3Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 4Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 5Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 6Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 7Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 8Health News:Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO 2Health News:Support for Patient Navigation Services to Help Cancer Patients 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 5
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... Ad-Techs Intraoperative Electrodes share ... electrodes. The main difference is ... discs are numbered to assist ... electrodes are designed for use ...
... the Selenia full field digital mammography ... new era in the world of ... innovation combines the latest advances in ... management capabilities to bring you the ...
... The P3000 heralds a new concept in ... binocular infrared optical system developed for the P2000. ... standard in which we have paid particular attention ... Our new system is extremely flexible, allowing ...
Medicine Products: